Sanofi provides update on phase-III study evaluating Rilzabrutinib to treat pemphigus
Rilzabrutinib’s safety profile remained consistent with previous results and no new safety signals were identified
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.